Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib and Pyrotinib in Advanced NSCLC
NCT04785729Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04785729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785729.